Drug recall · February 9, 2022
Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets 10 mg/10 mg recall
Why: Failed Dissolution Specification: Dissolution results are below specification limits for the active ingredient
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets 10 mg/10 mg, 100-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314, USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 007045 USA, NDC 0591-2132-01
- Lots / codes
Lot# 100025842, 100028023, Exp Date 08/2023
- Quantity
- 6205 100-count bottles
- Company
- Teva Pharmaceuticals USA, Parsippany, NJ
- Distribution
- Nationwide in the USA
- Initiated
- January 18, 2022 · Voluntary: Firm initiated
- Classified
- January 28, 2022
- Reported
- February 9, 2022
- Ended
- December 21, 2022
- How notified
- N/A
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Doxylamine / pyridoxine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.